Avalo Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:AVTX

Comments

Avalo Therapeutics Inc Earnings Estimates

AVTXNASDAQ

Trade with Public

$15.80

-0.91-5.45%

At close: Mar 13, 5:00 PM EST

$16.78

0.986.20%

After Hours: Mar 12, 7:16 PM EST

Overview NewsEarningsOptions Analyst Ratings Insider Trades Short Interest Stock Report

Avalo Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:AVTX

Avalo Therapeutics (AVTX) is scheduled to report Q4 earnings on March 27, 2026. Analysts estimate EPS of $-1.51 and quarterly revenue of N/A.

In the most recent quarter (Q3), Avalo Therapeutics reported EPS of $-2.19, missing estimates of $-1.65 by 0.33%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Avalo Therapeutics has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Avalo Therapeutics has averaged an EPS surprise of 0.78% and a revenue surprise of 0.00%.

Earnings Date

Mar 27

EPS Estimate

$-1.510

Quarterly Revenue Estimate

–

Annual Revenue

–

Avalo Therapeutics Earnings History

Analyze the earnings history of Avalo Therapeutics using advanced sorting and filters.

Loading calendar...

Avalo Therapeutics (AVTX) Earnings Per Share

The chart below shows Avalo Therapeutics's reported EPS compared to analyst estimates over recent quarters.

Avalo Therapeutics (AVTX) Revenue

The chart below shows Avalo Therapeutics's reported revenue compared to analyst estimates over recent quarters.

FAQ

When is Avalo Therapeutics (NASDAQ:AVTX) reporting earnings?

Avalo Therapeutics (AVTX) is scheduled to report earnings on May 11, 2026. The last reported earnings were for reported on November 6, 2025 for Q3.

What were the latest earnings per share (EPS) for Avalo Therapeutics (NASDAQ:AVTX)?

The Actual EPS was $-2.19, which missed the estimate of $-1.65.

What were Avalo Therapeutics’s (NASDAQ:AVTX) revenues?

The Actual Revenue was $0.00, which hit the estimate of $0.00.

People Also Watch

Voyager Therapeutics Inc

Silence Therapeutics PLC

NASDAQ:SLN

$6.90

NovaBridge Biosciences

NASDAQ:NBP

$2.94

3.74%

Camp4 Therapeutics Corp

NASDAQ:CAMP

$5.21

-3.70%

Minerva Neurosciences Inc

NASDAQ:NERV

$7.70

-1.66%

Avalo Therapeutics Earnings Estimates, EPS & Revenue | NASDAQ:AVTX

Avalo Therapeutics (AVTX) is scheduled to report Q4 earnings on March 27, 2026. Analysts estimate EPS of $-1.51 and quarterly revenue of N/A.

In the most recent quarter (Q3), Avalo Therapeutics reported EPS of $-2.19, missing estimates of $-1.65 by 0.33%. Revenue came in at $0.00, meeting the estimate of $0.00 by 0.00%.

Avalo Therapeutics has missed EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, Avalo Therapeutics has averaged an EPS surprise of 0.78% and a revenue surprise of 0.00%.

Earnings Date

Mar 27

EPS Estimate

$-1.510

Quarterly Revenue Estimate

–

Annual Revenue

–